MILANO VINCENT 4

What Happened

• Vincent Milano, a director at BioCryst Pharmaceuticals (BCRX), was issued 1,122 shares as an award/acquisition on May 29, 2026. The shares were recorded at $8.91 per share, for a total reported value of $9,997.
• This issuance represents shares given in lieu of 50% of his quarterly board chair cash retainer (50% of $20,000), i.e., a compensation conversion rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-05-29; reported filing date: 2026-06-02 (filing appears to be within the normal Form 4 reporting window).
• Price per share: $8.91; shares acquired: 1,122; total value reported: $9,997.
• Shares were issued in lieu of 50% of the quarterly cash Board Chair retainer (footnote F1).
• Shares owned after the transaction: not specified in the information provided.
• Transaction code: A (award/acquisition); not a market purchase or sale.

Context

• This was a compensation-related issuance (director fee conversion). Such awards are routine corporate compensation and do not necessarily signal the director’s personal buying or selling intent.
• For retail investors, compensation issuances are informative about executive/director pay practices but are less directly indicative of insider sentiment than open-market buys or sells.